Guardant Health Inc Cash Flow Conversion Efficiency
Guardant Health Inc cash flow conversion efficiency. Based on the latest financial reports, Guardant Health Inc (GH) has a cash flow conversion efficiency ratio of 0.362x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-65.62 Million) by net assets ($-181.07 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Guardant Health Inc (2016–2025)
Cash flow conversion efficiency of Guardant Health Inc from 2016 to 2025. This chart illustrates how Guardant Health Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Guardant Health Inc for real-time trading data and today's change.
Guardant Health Inc Cash Flow Conversion Ratio Explained
Guardant Health Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Guardant Health Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Guardant Health Inc ranked by their cash flow conversion efficiency. Also see GH company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Taiwan Mobile Co Ltd
TW:3045
|
0.110x |
|
GRAB HOLDINGS LTD CL.A
F:A6I
|
0.010x |
|
BridgeBio Pharma Inc
NASDAQ:BBIO
|
0.028x |
|
Yunnan Aluminium Co Ltd
SHE:000807
|
0.090x |
|
Wolters Kluwer N.V.
AS:WKL
|
1.252x |
|
Henan Shuanghui Investment & Development Co Ltd
SHE:000895
|
0.066x |
|
LATAM Airlines Group S.A.
NYSE:LTM
|
0.484x |
|
SEI Investments Company
NASDAQ:SEIC
|
0.050x |
Annual Cash Flow Conversion Efficiency for Guardant Health Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Guardant Health Inc from 2016 to 2025. Review Guardant Health Inc free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-99.31 Million | $-184.76 Million | 1.860x | +8.32% |
| 2024-12-31 | $-139.65 Million | $-239.86 Million | 1.718x | +183.87% |
| 2023-12-31 | $158.68 Million | $-324.98 Million | -2.048x | +60.17% |
| 2022-12-31 | $60.18 Million | $-309.46 Million | -5.142x | -1486.86% |
| 2021-12-31 | $645.00 Million | $-209.02 Million | -0.324x | -322.69% |
| 2020-12-31 | $1.36 Billion | $-103.93 Million | -0.077x | -37.93% |
| 2019-12-31 | $847.99 Million | $-47.13 Million | -0.056x | +59.58% |
| 2018-12-31 | $524.95 Million | $-72.19 Million | -0.138x | +41.25% |
| 2017-12-31 | $308.61 Million | $-72.23 Million | -0.234x | +49.18% |
| 2016-12-31 | $79.70 Million | $-36.71 Million | -0.461x | -- |
About Guardant Health Inc
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tu… Read more